Cargando…
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer
RAS mutant (MT) metastatic colorectal cancer (mCRC) is resistant to MEK1/2 inhibition and remains a difficult-to-treat group. Therefore, there is an unmet need for novel treatment options for RASMT mCRC. RALA and RALB GTPases function downstream of RAS and have been found to be key regulators of sev...
Autores principales: | Khawaja, Hajrah, Campbell, Andrew, Roberts, Jamie Z., Javadi, Arman, O’Reilly, Paul, McArt, Darragh, Allen, Wendy L., Majkut, Joanna, Rehm, Markus, Bardelli, Alberto, Di Nicolantonio, Federica, Scott, Christopher J., Kennedy, Richard, Vitale, Nicolas, Harrison, Timothy, Sansom, Owen J., Longley, Daniel B., Evergren, Emma, Van Schaeybroeck, Sandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596570/ https://www.ncbi.nlm.nih.gov/pubmed/33122623 http://dx.doi.org/10.1038/s41419-020-03131-3 |
Ejemplares similares
-
A fully automated procedure for the parallel, multidimensional purification and nucleotide loading of the human GTPases KRas, Rac1 and RalB
por: Gray, Christopher H., et al.
Publicado: (2017) -
The SCF(Skp2) ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L)
por: Roberts, Jamie Z., et al.
Publicado: (2020) -
Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023) -
Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer
por: Bradley, Conor A., et al.
Publicado: (2016) -
KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies
por: Wen, Qing, et al.
Publicado: (2016)